Effects of Sitagliptin in Individuals With Genetically Decreased DPP4

Summary

This is a pilot clinical trial to test the hypothesis that during sitagliptin (DPP4 inhibitor), individuals heterozygous for DPP4 loss of function variants will have a reduction in DPP4 activity and antigen, lower glucose after a mixed meal, and higher levels of intact DPP4 substrates compared to during placebo and compared to matched controls.

Timeline

Start

2020-08-26

Primary completion

2025-02-27

Completion

2026-02-28

Drugs

Indications